ReviewBioMed research international2018
Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review.Eye (London, England) · 2023Pooled it
- How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview.Advances in therapy · 2019Pooled it
- Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.JAMA ophthalmology · 2020Trial
- Retinal fluid segmentation in real-world OCT imaging of neovascular AMD using hybrid deep learning and graph-based optimization.Biomedical optics express · 2026Article
- OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration.BMC ophthalmology · 2026Article
- Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.Ophthalmology and therapy · 2025Article
- Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration.International journal of retina and vitreous · 2025Article
- Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period.PloS one · 2025Article
- Therapeutic Effects of Taurine and Histidine Supplementation in Retinal Diseases.Life (Basel, Switzerland) · 2024Review
- Preserving visual acuity: a compelling 12-year case study of controlling neovascular age-related macular degeneration.BMC ophthalmology · 2024Article
- Based on the Real-Life Data of Türkiye; Comparison of Anatomical and Functional Outcomes of Phakic and Pseudophakic Patients in Wet Type Age-Related Macular Degeneration.Beyoglu eye journal · 2023Article
- The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.Advances in therapy · 2022Article
- Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment.Journal of personalized medicine · 2021Article
- Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration.Journal of personalized medicine · 2021Article
- Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning.Ophthalmology · 2021Article
- External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration.Frontiers in medicine · 2021Article
- Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.Frontiers in immunology · 2021Observational
- Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration.Eye (London, England) · 2020Article
- Development and applications of artificial symmetrical proteins.Computational and structural biotechnology journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is one of the leading causes of severe vision loss in people over 60 years. Wet AMD (wAMD) causes more severe visual acuity (VA) loss compared with the dry form due to formation of choroidal neovascularization (CNV). Antivascular endothelial growth factor (anti-VEGF) agents such as ranibizumab and aflibercept are now the standard of care treatment for wAMD. Unfortunately, up to a quarter of anti-VEGF-treated wAMD patients might not fully benefit from intravitreal injections and CNV activity may not respond to the treatment and these patients are called anti-VEGF nonresponders. This article aims to discuss the baseline factors associated with VA outcome such as age, initial VA, lesion types, disease duration, optical coherence tomography (OCT) features, fundus autofluorescence findings, and the presence of particular genotype risk alleles in patients with wAMD. Recommendations are provided regarding when to consider discontinuation of therapy because of either success or futility. Understanding the predictive factors associated with VA outcome and treatment frequency response to anti-VEGF therapy may help retina specialists to manage patients' expectations and guide treatment decisions from the beginning of treatment on the basis of "personalized medicine."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.